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Abstract
Background:  The human gene ERH  (Enhancer of the Rudimentary gene Homologue) has
previously been identified by in silico analysis of four million ESTs as a gene differentially expressed
in breast cancer. The biological function of ERH protein has not been fully elucidated, however
functions in cell cycle progression, pyrimidine metabolism a possible interaction with p21(Cip1/
Waf1) via the Ciz1 zinc finger protein have been suggested. The aim of the present study was a
systematic characterization of ERH expression in human breast cancer in order to evaluate possible
clinical applications of this molecule.
Methods: The expression pattern of ERH was analyzed using multiple tissue northern blots (MTN)
on a panel of 16 normal human tissues and two sets of malignant/normal breast and ovarian tissue
samples. ERH expression was further analyzed in breast cancer and normal breast tissues and in
tumorigenic as well as non-tumorigenic breast cancer cell lines, using quantitative RT-PCR and non-
radioisotopic in situ hybridization (ISH).
Results: Among normal human tissues, ERH expression was most abundant in testis, heart, ovary,
prostate, and liver. In the two MTN sets of malignant/normal breast and ovarian tissue,ERH was
clearly more abundantly expressed in all tumours than in normal tissue samples. Quantitative RT-
PCR analyses showed that ERH expression was significantly more abundant in tumorigenic than in
non-tumorigenic breast cancer cell lines (4.5-fold; p = 0.05, two-tailed Mann-Whitney U-test); the
same trend was noted in a set of 25 primary invasive breast cancers and 16 normal breast tissue
samples (2.5-fold; p = 0.1). These findings were further confirmed by non-radioisotopic ISH in
human breast cancer and normal breast tissue.
Conclusion: ERH expression is clearly up-regulated in malignant as compared with benign breast
cells both in primary human breast cancer and in cell models of breast cancer. Since similar results
were obtained for ovarian cancer, ERH overexpression may be implicated in the initiation and/or
progression of certain human malignancies. Further studies on large breast cancer tissue cohorts
should determine whether ERH could function as a prognostic factor or even a drug target in the
treatment of human breast cancer.
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Background
The human ERH  (Enhancer of the Rudimentary gene
Homologue) gene encodes a protein highly conserved
among eukaryotes. It has been identified after comparison
of human ESTs with known genes in public databases, as
a gene highly homologous to the enhancer of the rudi-
mentary gene (DROER) in Drosophila melanogaster [1]. The
human  ERH  consists of 797 nucleotides, including an
open reading frame of 312 nucleotides, encoding a pro-
tein of 104 amino acids. ERH has been mapped to the
chromosomal band 7q34 by fluorescence in situ hybridi-
zation, and its expression was originally found in all nor-
mal human tissues examined [1]. Details on the
purification and crystallization of the human ERH protein
have been reported recently [2].
Intriguingly, the enhancer of the rudimentary gene –
named ERH in humans, er(h) in all non-human species,
DROER in Drosophila and XERH in Xenopus – is highly
conserved among vertebrates, invertebrates, and plants
with various orthologs identified, while there are no
homologous sequences known within the same species
[3-5]. The human and mouse coding regions are 93%
identical, and the amino acid sequence of their proteins
are completely identical to each other, as well as to that of
the frog (Xenopus laevis) [3,4]. Furthermore, the human
ERH protein has a 79.8% identity in amino acid sequence
to that of D. melanogaster [1]. Similarly impressive is the
conservation of hydrophobic amino acids: Of the 27 posi-
tions occupied by hydrophobic amino acids in DROER,
25 (93%) are conserved in the mosquito and human, 23
Table 1: Baseline characteristics of primary breast carcinomas (n = 25)
Variable Categorization n analyzablea %
Clinico-pathologic data:
Age at diagnosis
median 63.7 years (range 35–83 years)
<50 years 3 12
= 50 years 22 88
Tumour stageb
pT1 10 40
pT2 10 40
pT3 3 12
pT4 2 8
Lymph node statusb
pN0 12 48
pN1 1 4
pN2 8 32
pN3 4 16
Histologic grade
G1 0 0
G2 10 40
G3 15 60
Histologic type
ductal 20 80
lobular 3 12
mixed ductal/lobular 1 4
other 1 4
Immunohistochemistry (IHC):
Estrogen receptor status
negative (IRSc 0–2) 5 20
positive (IRS 3–12) 20 80
Progesterone receptor status
negative (IRS 0–2) 7 28
positive (IRS 3–12) 18 72
HER2 IHC
unknown 2 8
negative (0–1+) 19 76
positive (2+–3+) 4 16
a only female patients with primary, unilateral, invasive breast cancer were included
b according to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds.) Wiley, New York.
c IRS: immune-reactivity scoreBMC Cancer 2008, 8:145 http://www.biomedcentral.com/1471-2407/8/145
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(85%) in the nematode (C. elegans), and 20 (74%) in the
Arapidopsis thaliana protein [3].
Using the in silico method electronic Northern (eNorth-
ern) for RNA expression profiling, we have previously
identified a genetic signature containing hundreds of can-
didate genes differentially expressed in breast and ovarian
cancer [6]. Characterization of a subset of these candidate
genes, by cDNA dot blot using cancer profiling arrays,
real-time RT-PCR, non radioisotopic RNA in situ hybridi-
zation (ISH) and immunohistochemistry has been
reported elsewhere [7-11]. ERH was identified by this in
silico approach among other genes, and this gave us the
impetus to further study its expression in human breast
cancer. In the present study, we present a systematic
expression analysis of ERH in a panel of breast cancer cell
lines and malignant and normal human breast tissue sam-
ples using Northern blot, quantitative RT-PCR and non-
radioisotopic RNA ISH.
Methods
Tissue Specimens and RNA extraction
Formalin-fixed paraffin-embedded tissue from breast can-
cer and corresponding normal tissue specimens were
obtained from patients treated at the Gynaecology
Department of the University Hospital of Aachen, with
institutional review board approval. The cohort of breast
tissue specimens analyzed in this study (25 human inva-
sive breast cancers and 16 unmatched normal breast tis-
sues) has been described previously [9]. The
histopathological data of the tumours are summarized in
Table 1. For each formalin-fixed paraffin-embedded tissue
specimen six 4-μm thick tissue sections were cut with a
microtome (Leica, Wetzlar, Germany) and transferred to a
water bath filled with DEPC-treated water. Sections were
mounted on standard glass slides, dried for 1 h at 60°C,
and deparaffinized and rehydrated as follows: 2 × 15 min
in xylole, 2 × 15 min in 100% ethanol, and short rinses in
96%, 70%, 50% ethanol followed by emersion in distilled
water. Tissue material was transferred to a microcentrifuge
tube and RNA was extracted according to the Trizol proto-
col supplied by the manufacturer (Life Technologies,
Mannheim, Germany).
Cell lines and RNA extraction
The non-tumorigenic breast cancer cell lines MCF12A and
MCF10A, and five tumorigenic breast cancer cell lines
(MCF7, SKBR3, T47D, ZR75-1, and BT-20) were obtained
from the American Type Culture Collection (ATCC, Rock-
ville, MD, USA) and cultured under recommended condi-
tions. RNA from cell lines was extracted using the Trizol
protocol (see above).
RNA expression analysis by northern blot in normal and 
malignant human tissues
ERH expression was analyzed by multiple tissue northern
blots (MTN) in a panel of 16 normal tissues, a set of four
matched breast cancer/normal breast, and a set of four
matched ovarian cancer/normal ovarian tissue samples
(Clontech, Heidelberg, Germany). The following normal
tissues were analyzed: heart, brain, placenta, lung, liver,
skeletal muscle, kidney, pancreas, spleen, thymus, pros-
tate, testis, ovary, small intestine, colon, and peripheral
blood leukocytes. The breast cancer MTN contained four
pairs of invasive ductal carcinoma and matched normal
breast tissue from four female patients (51, 36, 47, and 45
years old). The ovarian cancer MTN contained four pairs
of malignant and normal ovarian tissue from four female
patients (age 48 – serous papillary cystadenocarcinoma;
age 30 – papillary cystadenocarcinoma; age 42 – granu-
losa-theca cell tumour; age 28 – adenocarcinoma).
Hybridization was performed using 25 ng of a gene-spe-
cific  32P-labeled DNA probe derived from a Unigene
cDNA clone [GenBank accession number W33000]. This
gene-specific cDNA fragment was radiolabelled using a
Megaprime labelling kit (Amersham Biosciences, Braun-
schweig, Germany), hybridized overnight at 68°C using
ExpressHyb Hybridization Solution (Clontech, Heidel-
berg, Germany), washed, and exposed to Kodak XAR-5 X-
ray film with an intensifying screen (Eastman Kodak Co,
Rochester, NY).
Quantitative RT-PCR
ERH mRNA-expression was analyzed with the LightCy-
cler® system (Roche Diagnostics, Germany) in non-tumor-
igenic and tumorigenic breast cancer cell lines, and
formalin-fixed paraffin-embedded breast cancer and nor-
mal breast tissue specimens. GAPDH mRNA was used as
reference to obtain relative expression values. Primers
used are presented in Table 2. Real-time RT-PCR was car-
ried out with Fast Start DNA master hybridization probes
(Roche Molecular Biochemicals, Germany). PCR condi-
tions were as follows: initial denaturation in one cycle of
15 min at 95°C, followed by 40 cycles at 95°C for 20 sec,
60°C for 20 sec and 72°C for 30 sec. Reaction, data acqui-
sition, and analysis were all done by using the LightCy-
cler® instrument.
Table 2: Primers and probes used in real-time RT-PCR
Gene Primer sequence Product size
ERH 5'-TGAATCCCAACAGTCCCTCT-3' 163 bp
5'-CGACGAAGGAGCACGTAGAT-3'
GAPDH 5'-TGGTCACCAGGGCTGCTT-3'† 151 bp
5'-AGCTTCCCGTTCTCAGCCTT-3'†BMC Cancer 2008, 8:145 http://www.biomedcentral.com/1471-2407/8/145
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Non-radioisotopic RNA in situ hybridization
Non-radioisotopic RNA ISH was performed as previously
described [7,9]. In brief, riboprobes were obtained from
plasmids containing cDNA inserts from the same clones
used for array hybridization, linearized with restriction
enzymes. Probes were digoxigenin-labeled using the Dig
RNA labelling kit (Roche Applied Science, Mannheim,
Germany). Paraffin embedded tissue specimens were
deparaffinized, re-hydrated, washed two times in PBS,
and processed according to the manufacturer's instruc-
tions (Roche Applied Science, Mannheim, Germany).
Hybridized probes were detected using alkaline phos-
phatase conjugated anti-DIG antibodies and BM Purple as
substrate (Roche Applied Science, Mannheim, Germany).
After nuclear fast red counter staining (containing 5% alu-
minium sulphate; VWR International, Dublin, Ireland)
sections were examined by a pathologist.
Statistical analysis
In order to compare the delta CT values of the real time
RT-PCR results between specific groups the non-paramet-
ric Mann-Whitney-U-test was used.
Results
Expression analysis using multiple tissue Northern blots
ERH expression was detected by multiple tissue Northern
blots (MTN) in all 16 normal human tissues analyzed
(Clontech, Heidelberg, Germany). ERH  expression was
most abundant in testis compared with other normal tis-
sues. Abundant ERH expression was also found in normal
tissue from the heart, ovary, prostate, and liver. Less abun-
dant expression was detected in the remaining 11 normal
tissues, with weakest expression in normal lung tissue.
These results are presented in Figure 1.
ERH expression was further analyzed by MTN in a set of
four matched breast cancer/normal breast tissue samples,
and a set of four malignant/normal ovarian tissue samples
(Clontech, Heidelberg, Germany). ERH  expression was
detectable in all malignant and normal breast tissue sam-
ples, and expression was clearly stronger in all tumour
samples as compared with normal tissue samples (Figure
2, upper panel). The same expression pattern of more
abundant expression in tumour compared with normal
tissue samples was also seen in ovarian cancer (Figure 2,
lower panel).
Quantitative RT-PCR
In order to investigate the possibility that ERH might be
differentially expressed in different stages of mammary
tumour progression we have compared ERH mRNA levels
in non-tumorigenic (i.e. MCF10A and MCF12A cells) and
five different tumorigenic breast cancer cell lines with
LightCycler®  RT-PCR (Figure 3). We found that ERH
expression was significantly more abundant in tumori-
genic cell lines as compared with non-tumorigenic cell
lines (p = 0.05 according to two-tailed Mann-Whitney U-
test). Interestingly, ERH was very abundantly expressed in
the highly metastatic breast cancer cell line BT20. These
results are presented diagrammatically in Figure 3.
ERH expression was further validated by real-time RT-PCR
using the LightCycler® system in a set of formalin-fixed
paraffin-embedded tissue specimens, consisting of 25 pri-
mary invasive breast cancers and 16 normal breast tissue
samples. These data are diagrammatically presented in
Figure 4. Consistently with the MTN results presented
above, mean ERH expression in breast tumours was 2.5
fold more abundant than mean ERH expression in nor-
mal breast tissue (p = 0.1 according to two-tailed Mann-
Whitney U-test).
ERH expression in human normal tissues analyzed by Northern blot hybridization Figure 1
ERH expression in human normal tissues analyzed by Northern blot hybridization. Strong ERH mRNA expression 
was found in normal testis, heart, ovary, prostate and liver. Less abundant ERH mRNA was detected in the remaining 11 tissues 
tested. The human ERH transcript is approximately 1.2 kb in size.
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Cellular localization of ERH mRNA
Cellular localization of ERH mRNA in breast cancer and
normal breast tissue was analyzed with non-radioactive
RNA ISH. ERH expression was up-regulated in breast can-
cer as compared with normal breast tissue. Representative
sections showing ERH expression as detected by ISH are
presented in Figure 5. ERH  was specifically and abun-
dantly expressed in the tumour cells of invasive ductal car-
cinoma (D, G), while a less abundant ERH  mRNA
expression could be detected in the epithelial cells of nor-
mal breast lobuli (A).
Discussion
Thus far, a variety of different functions have been attrib-
uted to the ERH protein, including enhancement of pyri-
midine biosynthesis, a role in cell cycle regulation, cell
growth, repression of transcription and interaction with
p21(Cip1/Waf1) [4,12-14]. Moreover, little is known
about the role of ERH  in human malignancies. In the
present study, the gene expression pattern of ERH  has
been systematically analyzed in normal human tissues,
breast cancer cell lines and a panel of malignant and nor-
mal human breast and ovarian tissue samples using three
independent methods. Our analysis provides useful
insights regarding the still inconsistently defined biologi-
cal role of ERH. It is furthermore the first study to supply
a systematic data set concerning ERH  expression in a
human malignancy.
The Enhancer of rudimentary gene was first discovered in
Drosophila melanogaster: Mutations of the rudimentary gene
(r), encoding a multifunctional protein for the first three
enzymatic activities of the pyrimidine biosynthetic path-
way, lead to a characteristic truncation of the wings. Muta-
tion of another gene led to more severely truncated wings
in the background of r-mutations, and thus this gene was
named Enhancer of the rudimentary [5]. Later studies pro-
vided experimental evidence suggesting that the wild-type
ERH protein is a transcriptional (co-)repressor [4,15,16]
and its activity is not restricted to the pyrimidine biosyn-
thetic pathway. Another hypothesis was based on the
observation that ERH is only weakly expressed in non-
dividing cell lines of hepatocytes while it is abundantly
expressed in fibroblast and hepatoma cell lines, suggest-
ERH expression in breast and ovarian cancer and normal tissue, analyzed by Northern blot Figure 2
ERH expression in breast and ovarian cancer and normal tissue, analyzed by Northern blot. ERH was expressed in 
all malignant and normal tissue samples. In both tumour entities, ERH expression was stronger in all tumour samples as com-
pared with matched and non-matched normal tissue samples. Upper panel: breast cancer; lower panel: ovarian cancer. IDC: 
invasive ductal carcinoma; SPCA: serous papillary cystadenocarcinoma; PCA: papillary cystadenocarcinoma; GPCT: granulosa-
theca cell tumour; AC: adenocarcinoma.
breast cancer
ovarian cancer
IDC       N      IDC     N      IDC   N       IDC     N
SPCA      N   PCA      N    GTCT    N  AC       N
1.2 kb
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ing that ERH might have a function necessary for normal
cellular proliferation [3].
However, our findings do not support a key role of ERH
in cellular proliferation, since ERH seems to be heteroge-
neously expressed in normal tissues expected to be tran-
scriptionally active (more abundant expression in testis,
ovary, prostate, and liver, but lower expression in pla-
centa, kidney, pancreas, small intestine and colon – see
Figure 1), as well as heterogeneously expressed in termi-
ERH expression in benign and malignant breast cell lines. Diagrammatic presentation of quantitative RT-PCR data Figure 3
ERH expression in benign and malignant breast cell lines. Diagrammatic presentation of quantitative RT-PCR 
data. ERH expression was analyzed by real-time RT-PCR in the benign human breast cell lines MCF10A and MCF12A (grey 
columns) and in five breast cancer cell lines (black columns). ERH expression, normalized to MCF12A cells (set = 1.0), was sig-
nificantly more abundant in breast cancer cell lines as compared with benign cell lines (p = 0.05).
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ERH expression in normal and malignant breast tissue. Diagrammatic presentation of quantitative RT-PCR data Figure 4
ERH expression in normal and malignant breast tissue. Diagrammatic presentation of quantitative RT-PCR 
data. ERH expression was analyzed by real-time RT-PCR in formalin-fixed paraffin-embedded tissue specimens. Mean ERH 
expression was 2.5-fold more abundant in breast tumours as compared to normal breast tissue (mean expression in normal 
breast was set = 1.0). N: normal breast; T: invasive breast cancer.
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nally differentiated tissues expected to have low transcrip-
tional activity (very weak expression in lung, brain and
peripheral blood leucocytes, but abundant in heart and
skeletal muscle – see Figure 1).
Based on our finding that ERH is abundantly expressed in
the majority of normal human tissues analyzed, it does
not appear to be an ideal therapeutic drug target in human
cancer treatment, but still such a role cannot be com-
pletely excluded. On the other hand, more abundant ERH
expression in tumorigenic as compared with non-tumori-
genic breast cancer cell lines (see Figure 3) and the trend
of higher expression in malignant as compared with nor-
mal tissue samples (see Figure 4) suggest that ERH could
be possibly used as a prognostic factor in breast cancer.
Since similar results were obtained for ovarian cancer (see
Figure 2), the expression pattern and the prognostic role
of ERH in breast cancer and gynecologic malignancies
awaits evaluation in future studies. Furthermore, this
expression pattern suggests that ERH might be implicated
in carcinogenesis and tumour-progression and this
should be further investigated in appropriately designed
functional studies.
Conclusion
ERH expression is clearly up-regulated in tumorigenic as
compared with non-tumorigenic breast cancer cell lines
(found by quantitative RT-PCR), and in malignant as
compared with normal breast tissue samples (confirmed
by three independent methods, i.e. MTN, quantitative RT-
Representative sections of ERH mRNA expression as detected by non-radioactive in situ hybridization (ISH) Figure 5
Representative sections of ERH mRNA expression as detected by non-radioactive in situ hybridization (ISH). A, 
D, and G: Hybridization with antisense ERH probe demonstrates ERH mRNA expression. B, E, and H: Hybridization with sense 
ERH probe serves as negative control for the specificity of the antisense probe. C, F, I: Hematoxylin-eosin staining of consecu-
tive sections shown in ISH. ERH mRNA was clearly detectable in epithelial cells from invasive breast cancer (D, G), while a less 
abundant ERH mRNA expression could be detected in epithelial cells of normal breast tissue (A).BMC Cancer 2008, 8:145 http://www.biomedcentral.com/1471-2407/8/145
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PCR, and non-radioisotopic ISH). These findings suggest
that ERH is progressively up-regulated with tumour pro-
gression, and thus it could be used as a prognostic factor
in breast cancer. A similar expression pattern was also
found in ovarian cancer (by MTN), suggesting that ERH
overexpression might be implicated in the initiation and/
or progression of other human malignancies as well. Fur-
ther studies on large breast cancer tissue cohorts are nec-
essary in order to investigate whether ERH could function
as a prognostic factor or even a drug target in the treat-
ment of human breast cancer, while functional studies
should delineate its possible role in carcinogenesis and
tumour-progression.
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